Skip to main content
Clinical Trials/NCT01213537
NCT01213537
Completed
Not Applicable

A Study of the Effect of Cardiac Resynchronisation Therapy (CRT) on Chemosensitivity in Patients With Chronic Heart Failure With and Without Sleep Disordered Breathing.

Imperial College London1 site in 1 country182 target enrollmentOctober 2010
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Imperial College London
Enrollment
182
Locations
1
Primary Endpoint
Change in chemosensitivity before and after CRT implantation
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

This study aims to investigate the effect of a pacemaker device used in heart failure patients which is called Cardiac Resynchronisation Therapy (CRT). Specifically the investigators aim to investigate if the CRT pacemaker has an effect on breathing stability in these patients and particularly breathing stability at night. Our theory is that the CRT pacemaker may improve the stability of breathing in patients with heart failure.

Detailed Description

AIM To investigate the effect of Cardiac Resynchronisation Therapy (CRT) on chemosensitivity in patients with Chronic Heart Failure with and without Sleep Disordered Breathing (SDB). OBJECTIVE To conduct a physiological observational study to measure hypercapnic ventilatory responses in a group of CHF patients before and 3 months after implantation of clinically indicated CRT devices. Additionally to conduct nocturnal polysomnography to establish if any change in chemosensitivity is related to the presence of SDB at baseline and, where present, any change in SDB after implantation. HYPOTHESIS Primary hypothesis: CRT implantation will be associated with a reduction in the hypercapnic ventilatory response from baseline to 3 months post implantation. Additional hypothesis: This reduction in hypercapnic ventilatory response after CRT implantation will be greatest in those CHF patients with SDB at baseline.

Registry
clinicaltrials.gov
Start Date
October 2010
End Date
October 2011
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Rebecca Lucas

Mrs

Imperial College London

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years old
  • Fulfil the current guidance for the implantation of a CRT device; optimal medical treatment for heart failure, broad QRS complex on electrocardiogram with or without evidence of cardiac dyssynchrony as appropriate, LVEF \<35%, functional impairment as defined by an NYHA class of III-IV
  • Clinically stable with no unplanned admission to hospital for preceding 4 weeks
  • No changes in medications for heart failure in preceding 4 weeks
  • Able to read and understand patient information sheet and give informed consent

Exclusion Criteria

  • On positive pressure treatment for known sleep disordered breathing at the time of inclusion
  • Other known condition (untreated) likely to significantly disturb sleep eg. Restless legs syndrome, pain from any cause etc.

Outcomes

Primary Outcomes

Change in chemosensitivity before and after CRT implantation

Time Frame: 3 months

We will look primarily at the effect of CRT implantation on chemosensitity which we will measure using the ventilatory sensitivity to carbon dioxide.

Study Sites (1)

Loading locations...

Similar Trials